4.4 Review

Anti-CD3 mAbs for treatment of type 1 diabetes

期刊

DIABETES-METABOLISM RESEARCH AND REVIEWS
卷 25, 期 4, 页码 302-306

出版社

WILEY
DOI: 10.1002/dmrr.933

关键词

type 1 diabetes; anti-CD3 antibody; immune modulation; immunologic tolerence

资金

  1. JDRF [2006-351, 2007502, 2007-1059, UL1 M02139]
  2. Brehm Foundation
  3. Friends United for Diabetes Research
  4. [RO1 DK DK057846]
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057846] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The use of anti-CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti-human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non-FcR binding antibodies: Teplizumab, Otelixizumab and Visilizumab. Preclinical studies showed the ability of the drugs to reverse hyperglycaemia in diabetic non-obese diabetic (NOD) mice providing rationale for clinical trials with the agents. The former two drugs have been tested in subjects with new onset type 1 diabetes. They have both shown, in randomized clinical trials, an ability to reduce the loss of insulin production over the first 2 years of the disease. In addition, the need for exogenous insulin to maintain glucose control has been reduced. However, these agents alone do not restore normal glucose control, and future approaches will likely require combinations of agents with complementary immune or metabolic activity. Copyright (C) 2009 John Wiley & Sons, Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据